PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-4.42
Negative P/E while Biotechnology median is -7.15. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
3.05
P/B near Biotechnology median of 3.25. Charlie Munger would verify if similar multiples reflect similar business quality.
-19.81
Negative FCF while Biotechnology median P/FCF is -28.24. Seth Klarman would investigate cash flow improvement potential.
-19.96
Negative operating cash flow while Biotechnology median P/OCF is -26.88. Seth Klarman would investigate operational improvement potential.
3.05
Fair value ratio near Biotechnology median of 3.25. Charlie Munger would verify if industry valuation norms make sense.
-5.65%
Negative earnings while Biotechnology median yield is -2.16%. Seth Klarman would investigate path to profitability.
-5.05%
Negative FCF while Biotechnology median yield is -1.64%. Seth Klarman would investigate cash flow improvement potential.